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1. Introduction 
Major depressive disorder (MDD) is a common psychiatric illness. Its 1-year prevalence 
rates varied in the different regions, for instance 5.1% in Australia, 6.7% in New Zealand, 
5.8% in Netherlands, 7.1% in Hungary, 6.2 in Italy, 15-23 % in Republic region of Udmurtia 
(rural area), 3.5%-10.3% in USA and 4.1%-4.6% in Canada (Handerson et al., 2000; Oakley-
Browne et al., 1989; Pakriev et al., 1998; Bijl et al., 1998; Szadoczky et al., 1998; Faravelli et al., 
1990; Bourdon et al., 1992; Offord et al., 1996; Bland et al., 1988). However, its prevalence in 
Taiwan is in a lower range of 0.6%-1.1% (Hwu et al., 1989). According to a meta-analysis of 
11 clinical studies, the mean average of its 1-year prevalence rate is 4.1% (95%CI, 2.4% to 
6.2%), and its sex-specific 1-year prevalence rates for men and women are 4.9% (95%CI, 3.3% 
to 7.1%) and 10.0% (95%CI, 6.4% to 14.6%) respectively (Waraich et al., 2004). The lifetime 
prevalence for MDD patients is  12.6% in New Zealand, 15.4% in Netherlands, 15.1% in 
Hungary, 13.1% in Italy, 15.7%-22.8% in Switzerland, 9.0% in Germany, 5.9%-17.1% in USA 
and 8.6%-29.6% in Canada (Oakley-Browne et al., 1989; Bijl et al., 1998; Szadoczky et al., 
1998, Carta et al., 1995; Wacker et al.1992; Wittchen et al., 1992 ; Kessler et al., 1994; Bourdon 
et al., 1992; Murphy et al., 2000; Fournier et al. 1997; Bland et al., 1988). For Asian countries, 
the prevalence is 1.9% in Hon Kong, 3.4% in Korea and 0.88%-1.7% in Taiwan (Chen et al., 
1993; Lee et al., 1987; Hwu et al., 1989). Its prevalence in Puerto Rico is 4.6% (Canino et al., 
1987). A meta-analyis of data obtained from several countries revealed that its lifetime 
prevalence is approximate 3.8% (95%CI, 2.4% to 23.1%) for men and 7.5% (95%CI, 4.5% to 
11.3%) for women (Waraich P, 2004). 
Depression is associated with various chronic medical conditions, including cardiovascular 
disease, hypertension, diabetes, arthritis and back pain. Recent evidence suggested that it is 
a primary risk factor for coronary heart disease (CHD), including myocardial infarction (MI) 
and cardiac death (Lett et al., 2004; Rugulies, 2002). In the contrary, patients with myocardial 
infarction (MI) and cardiac death also have an increased risk of depression. Depression is 
also associated with hypertension (Patten, 2001; DiMatteo et al., 2002). Despite of the 
heterogeneity of results, depression was found to be a risk of poor adherence to 
antihypertensive medications (Eze-Nliam et al., 2010). 
Diabetic patients also have a high risk for depression. A systemic review has found that 
diabetes doubles the odds of comorbid depression (Anderson et al., 2001) and increases the 
risk for depression for 24% (Nouwen et al., 2010). In the contrary, depression also increases 
the risk of diabetes development. In addition, depression has been associated with 
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hyperglycemia, diabetic complications, functional disability and mortality among diabetic 
patients (Rustad et al., 2011). 
The relationship of arthritis and depression has been well documented. A recent study has 
shown a strong association of depression and functional severity of rheumatoid arthritis (RA) 
and its related diseases (Godha et al., 2010). Another study also suggested that depression is 
highly correlated with the disease activity of rheumatoid arthritis (RA), especially the number 
of swollen joints and joint functional class (Khongsaengdao et al., 2000). 
Depression is a major burden for individuals, communities and health services throughout 
the world. The study of global burden of diseases in the year 2000 indicates that depression 
is an important causes of disease burden accounting for 4.4% of total disability adjusted life 
years (DALYs) in the year 2000, which is almost 12% of all total years lived with disability 
worldwide (Ustün et al., 2004). Effective pharmacological and psychosocial interventions to 
resolve depressive symptoms promptly could be reduce this burden. 
Pharmacotherapy, psychotherapy and their combinations are effective treatment for MDD. 
Tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin–
norepinephrine reuptake inhibitors (SNRIs) are examples of medications approved for the 
treatment of MDD. Examples of effective psychotherapy techniques are cognitive therapy 
(CT), cognitive behavioural therapy (CBT), interpersonal therapy (IT) and mindfulness-
based cognitive therapy (MBCT). Although most patients respond to these interventions, a 
considerable proportion of them may not respond or only partially respond to them. 
Combined psychotherapy and pharmacotherapy is therefore a choice for the latter group of 
patients. 
The aim of this chapter is to summarize the efficacy and safety of CBT combined with 
antidepressants. However, the efficacy and safety of antidepressants alone and CBT alone 
are also addressed. 
2. Cognitive behavioral therapy 
2.1 Cognitive model of depression 
The cognitive model of depression is supported by several research findings. The cognitive 
theory addressed in several studies comprises of three components: cognitive triad in 
depression, negatively biased cognitive processing of stimuli and identifiable dysfunctional 
beliefs (Beck, 2005). 
The components of cognitive triad include the patterns of depressed patients interpreting 
experiences, viewing themselves and viewing future in a negative way. The first triad is the 
negative interpretation of experience. Persistently, depressed patients tend to interpret the 
interaction between themselves and environment as representation of defeat, deprivation and 
disparagement. They perceive that their lives are plentiful of burdens, obstacle and traumatic 
events. The second triad is the negative evaluation of the self. Patients view themselves as 
deficiency, inadequacy and worthlessness. They tend to regard themselves as having a 
physical, mental or moral defect. They usually reject themselves because of those unpleasant 
defects. The last triad is the negative expectation of future. Depressed patients assume that the 
current difficulties and suffering will last forever. Their lives have endless obstacles, 
frustration and deprivation. These cognitive distortions are cause of depression (Beck, 1967).  
There are some of common maintenance processes in the depressed patients. The vicious 
cycle linking a depressed mood with cognitive bias, and negative appraisal causes the 
negative view of self, then maintaining the depressive symptoms. The negative appraisals 
www.intechopen.com
 
Cognitive-Behavioural Therapy Combined with Antidepressants for Major Depressive Disorder 
 
311 
and depressive symptoms could reduce depressed patients’ activities usually providing the 
pleasure and sense of achievement for them, and thus the decreased activities continue the 
depression. The symptoms of depression and negative appraisal may decrease the ability to 
cope and deal with their difficulties. They may feel hopelessness and continue to be 
depressed (Wrestbrook et al. 2007). 
2.2 Cognitive behavioral therapy for depression 
CBT is a collaborative, short-term, structured, focused approach psychotherapeutic 
intervention. The aims of CBT are to help the patients to understand the relationship of 
cognitions, emotions or affect, behaviours and physiology influenced by external stimuli. In 
addition, it would educate the patients on two-way relationship between cognition and 
behaviour in which cognitive processes can influence behavioural patterns, and behavioural 
changes can influence cognition (Wright, 2006). 
For the treatment of depression, CBT allows to use several techniques. In the early phase of 
treatment, the behavioural technique such as exercise or activity scheduling is used to 
reduce the depressive symptoms. For instance, high level physical exercise appears to be 
effective in reducing the depressive symptoms, and behavioural activities could prevent the 
reduction of activity in depressed patients. Then, the early cognitive technique is used to 
distract the patients from their negative automatic thoughts (NATs) and/or to change the 
attitude toward them. Some depressive symptoms may be relieved or reduced. The last, 
main cognitive behavioural technique is applied. In this phase, the patients learn to identify 
the NATs and alternative thoughts, self monitoring, thought records or behavioural 
experiment to disconfirm their NATs and to prove alternative hypothesis. In addition, the 
therapist also teaches the depressed patient to use the problem solving skills to reduce the 
depressive symptoms and risk of suicide (Wrestbrook et al. 2007). 
Besides the treatment of depression, CBT is widely used for several mental health 
conditions, e.g. anxiety disorders, personality disorders, eating disorders and substance use 
disorders (Beltman et al., 2010; Hofmann & Smits, 2008; Linehan et al., 1991; Fairburn et al., 
1995; Magill et al., 2009). CBT adjunct with medications is also beneficial for schizophrenia 
and bipolar disorder (Turkington et al., 2004; da Costa et al., 2010). 
3. Treatment for major depressive disorder 
3.1 Short-term treatment (acute phase) (6-12 weeks) 
In this phase, the patient experiences severe symptoms of depression. The goal is to relieve 
those symptoms. Most patients turn to be a remission at the end of this phase. 
3.1.1 Antidepressants 
There have been several randomized-controlled trials and meta-analyses comparing the 
efficacy and tolerability of antidepressants among MDD patients. While the efficacy of most 
antidepressants is relatively comparable, their tolerability appears to be varied based on 
their mechanisms of action. 
3.1.1.1 Tricyclic antidepressants  
3.1.1.1.1 Tricyclic antidepressants vs. Placebo 
Several systemic reviews demonstrated the efficacy of tricyclic antidepressants (TCAs) for 
MDD. In a meta-analysis of 32 placebo-controlled trials with 4314 patients, Storosum et al. 
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(2001), compared the short-term efficacy of TCAs with placebo. Their results suggested that 
TCAs are effective in the short-term treatment of MDD. Another meta-analysis of Furukawa 
et al. (2003, 2002) including 35 studies (2013 participants) compared low-dose TCAs (75-100 
mg/day) withplacebo for the treatment of depression. The findings suggested that low dose 
TCAs is superior to placebo in term of response rates while the tolerability of those TCAs is 
not significantly different from placebo. 
Although several lines of evidence support that TCAs is effective for adult depression, their 
efficacy for depression in children and adolescents is still controversial. A meta-analysis of 
Hazell et al. (1995) reviewed 12 randomised controlled trials comparing the efficacy of 
tricyclic antidepressants with placebo in depressed children and adolescents. The review 
showed that TCAs might not be effective for the treatment of depression in this age group. 
Another meta-analysis of TCAs for depressive disorders in children and adolescents 
including nine randomized, placebo-controlled trials supports the earlier findings 
(Maneeton et al., 2000). 
3.1.1.1.2 Tricyclic antidepressants vs. selective serotonin reuptake inhibitors 
Several systemic reviews compared TCAs with SSRIs in the treatment of MDD. A meta-
analysis of efficacy and tolerability in hospitalized depressed patients suggested that some 
TCAs, in particular amitriptyline, may be superior to SSRIs. A dual action of both 5-HT and 
noradrenaline reuptake inhibitors of those TCAs may be a possible explanation for the 
superiority. However, the meta-analysis found that SSRIs had a modest advantage in terms 
of tolerability (Anderson 1998, 2000). 
In the contrary, a few systemic reviews found no superiority of TCAs over SSRIs. A meta-
analysis of 11 studies including 2,951 participants comparing SSRIs with TCAs in the 
treatment of depression showed that their efficacy were comparable but the TCA patients 
dropped out more frequently.  Another meta-analysis of 181 randomized clinical trials (47% 
were inpatients, and 53% were outpatients), compared amitriptyline with SSRIs (Barbui et 
al., 2004). Amitriptyline therapy was not superior to SSRIs in both outpatients and 
inpatients. 
A meta-analysis of Arroll et al. (2005) reviewed ten studies of TCAs and SSRIs as 
comparison to placebo for treatment of depression in primary care. One half of those studies 
were at low methodological quality, and nearly all studies were short-term trials (six to 
eight weeks). The review showed that TCAs and SSRIs are more effective than placebo. In 
addition, the efficacy of low-dose and high-dose TCAs is comparable. 
TCAs may be less tolerable than SSRIs. A meta-analysis of Anderson et al. (2000) reviewed 
62 randomized controlled trials including 6,029 patients with MDD comparing SSRIs with 
TCAs in term of treatment discontinuation. Most study durations of included trials were 
between four and eight weeks. The analysis showed that the discontinuation rate due to side 
effect but that not due to treatment failure was more in the TCA-treated patients. Another 
meta-analysis of randomized, controlled trials also revealed that the overall discontinuation 
rates of tricyclic/heterocyclic antidepressants were greater than those of SSRIs (Hotopf, et 
al., 1997). Another meta-analysis of Montgomery (2001) examined the efficacy and 
tolerability of paroxetine (n = 1924) and tricyclic antidepressants (TCAs; n = 1693) in the 
treatment of major depression, it included studies from 39 randomized, double-blind, 
parallel-group studies. The durations of all included studies were six weeks or less. The 
findings indicated that paroxetine and TCAs have comparable efficacy, but paroxetine is 
more tolerable. In addition, a meta-analysis of Montgomery et al. (1994) examined 42 
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published randomized controlled studies also shows a lower discontinuation rate due to 
side effects as compared with TCAs. 
From those reviews, most TCAs and SSRIs are effective in the treatment of MDD. The 
superiority of amitriptyline to SSRIs is still controversial. As compared with SSRIs, the 
adverse effects of TCAs are more common and severe. Low dose TCAs should be 
considered in depressed patients intolerable to the moderate and high doses. 
Numerous systemic reviews are conducted to summarize the efficacy and tolerability of 
SSRIs in treating elderly patients with depression. A meta-analysis of Dunbar (1995) 
including ten studies carried out in elderly depressed patients demonstrated that paroxetine 
is as effective as other agents (amitriptyline, clomipramine, doxepin, mianserin). However, 
the adverse effects of paroxetine might be less frequent and less. These findings suggested 
that paroxetine might be an alternative first-line treatment to elderly depressed patients. 
3.1.1.1.2 Tricyclic antidepressants vs. serotonin norepinephrine reuptake inhibitors 
Only few systemic reviews compared TCAs with serotonin norepinephrine reuptake 
inhibitors (SNRIs). A meta-analysis of van den Broek et al. (2009) compared venlafaxine and 
TCAs (imipramine, clomipramine, amitriptyline, nortriptyline and desipramine). The 
average doses of venlafaxine and TCAs were 103.5 and 106.1 mg/day respectively. This 
review did not find any significant difference of efficacy and tolerability between groups. 
3.1.1.2 Selective serotonin reuptake inhibitors 
Several systemic reviews have indicated that SSRIs are effective for MDD. In meta-analysis 
of Bech & Cialdella (1992), citalopram was more effective and more tolerable than placebo. 
Its dose of 20 mg/day may be enough for patients with mild depression or first depressive 
episode. However, 40 mg/day may be needed for those with severe or recurrent depression 
(Montgomery et al., 1994). Another meta-analysis of Tignol et al. (1992) reviewed 178 
patients treated with paroxetine and 66 patients treated with placebo and suggested that 
paroxetine is superior to placebo in the treatment of melancholic depression. 
Very few systemic reviews examined efficacy, safety and tolerability of SSRIs in depressed 
children and adolescents. A systemic review of published and unpublished randomised 
controlled trials comparing the efficacy and adverse events of SSRIs with placebo suggested 
that only fluoxetine therapy is effective. However the adverse events and risk of suicidal 
ideation and behaviour were increased the SSRIs-treated group (Hetrick et al., 2007). The 
meta-analyses of Whittington et al. (2004) and Usala et al. (2008) also supported the previous 
review. 
From several reviews, SSRIs is effective and acceptable in the treatment of MDD. However, 
in children and adolescents, fluoxetine may be the only one effective in this population. 
Since SSRIs have adverse effects and may increase the suicide risk, the use of them in this 
age group should carefully balance between the risk and its benefits. 
3.1.1.3 Serotonin norepinephrine reuptake inhibitors  
3.1.1.3.1 Serotonin norepinephrine reuptake inhibitors vs. Placebo 
Several systemic reviews have summarized the efficacy and acceptability of serotonin 
norepinephrine reuptake inhibitors (SNRIs) as comparison with placebo. A meta-analysis of 
six comparable double-blind placebo-controlled studies comparing venlafaxine with placebo 
indicated that it is effective for depression regardless of age, gender, presence of 
melancholia, and severity or duration of depression (Entsuah et al., 1995). In addition, 
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another meta-analysis also showed that venlafaxine is superior to placebo in reducing 
symptoms of anxiety in depressed patients (Rudolph et al., 1998). 
Desvenlafaxine is another SNRI that is effective, safe and well tolerated for patients with 
MDD. A pooled study of two studies showed that, after eight weeks of treatment, it is 
superior to placebo in the treatment of MDD. Its adverse effects are comparable to placebo 
(Lieberman et al., 2008). Another review of nine studies also demonstrated its short-term 
efficacy for MDD (Thase et al., 2009).  Another meta-analysis of eight clinical trials 
suggested that desvenlafaxine could improve the functioning and well-being among MDD 
patients (Soares et al., 2009). 
Several reviews have suggested that duloxetine at the doses of 40-60 mg/day is safe and 
effective in acute phase treatment of MDD (Mallinckrodt et al., 2006).  A meta-analysis of 
Mallinckrodt et al. (2005) reviewed eight double-blind, placebo-controlled clinical trials for 
up to nine weeks of treatment indicated that duloxetine was superior to placebo in the 
treatment of depressive disorder both melancholic and non-melancholic types. Another 
review of two 9-week trials, also demonstrated that duloxetine, as comparison to placebo, 
has a greater response rate at week two and a greater remission rate at week 5 (Hirschfeld et 
al., 2005). In addition, the significant difference of efficacy between male and female is not 
found (Kornstein et al., 2006). 
In comparison to venlafaxine, duloxetine may be less effective in the treatment of MDD. 
There is a systemic review of eight trials, including 1754 patients for efficacy and 791 
patients for discontinuation/safety, to compare the efficacy and safety of extended-release 
(XR) venlafaxine and duloxetine in treating MDD (Vis et al., 2005). The results showed that 
remission and response rates of venlafaxine were significantly greater than those of placebo 
and duloxetine. However the adverse events of both drugs are comparable. Another meta-
regression analysis also indicated that duloxetine appears to be less effective than 
venlafaxine in acute phase treatment of adult patients with MDD (Eckert & Lançon, 2006). 
From previous reviews, SNRIs are effective for MDD, with comparable tolerability to 
placebo. However, venlafaxine may be more effective than duloxetine. Venlafaxine, 
therefore, may be beneficial in patients with severe depressive symptoms. 
3.1.1.3.2 Serotonin norepinephrine reuptake inhibitors vs. Selective serotonin reuptake inhibitors 
Some reviews compared the efficacy between venlafaxine and SSRIs. Remission rate of 
MDD during venlafaxine treatment appear to be superior to SSRIs and placebo. A meta-
analysis of Thase et al. (2001) compared the remission rate in MDD of venlafaxine with 
SSRIs/placebo. The study showed that remission rate for venlafaxine is 45 %, while SSRIs 
and placebo are 35% and 25% respectively. The difference between venlafaxine and SSRIs 
appear to be significantly different at week 2 while the difference between SSRIs and 
placebo is significantly different at week 4. Another meta-analysis of eight double-blind, 
active-controlled, randomized clinical trials also demonstrated that the remission rate of 
venlafaxine in the treatment of MDD is higher than that of SSRIs (remission rate at week 8: 
venlafaxine, 40%-55% vs. SSRI, 31%-37%). The recent systemic review of remission between 
venlafaxine and SSRIs also supports those of findings (Nemeroff et al., 2008).  
Another systemic review of 32 double-blind, randomized, controlled trials compared 
venlafaxine with other antidepressants in the treatment of depression. Its findings indicated 
that venlafaxine was superior to SSRIs (Smith et al., 2002). Another meta-analysis of five six-
week, double-blind, randomized studies including 1,454 outpatients with major depression 
from comparing the efficacy of venlafaxine with fluoxetine showed that venlafaxine was not 
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only superior to but also had a more rapid onset of action than fluoxetine (Davidson et al., 
2002). The rapid onset of remission for venlafaxine treatment over SSRIs does not differ in 
age or gender (Entsuah et al., 2001). A recent systemic review comparing venlafaxine and 
TCAs or SSRIs in MDD also supports the previous reviews (Bauer et al., 2009). The findings 
showed that venlafaxine might be more effective than SSRIs, and at least as effective as 
TCAs, for the treatment of MDD and treatment-resistant depression. 
Not all systematic reviews support the greater efficacy of venlafaxine over SSRIs. A meta-
analysis of 17 trials summarized the remission, response and discontinuation rates between 
venlafaxine and SSRIs. The results demonstrated that a remission rate of venlafaxine is not 
superior to SSRIs, while response rate is only small significant over SSRIs (Weinmann et al., 
2008). 
Although venlafaxine may provide a highly effective antidepressant property, it tends to be 
associated with high blood pressure. A meta-analysis of venlafaxine affecting blood 
pressure summarized the results of controlled clinical trials including 3744 patients with 
major depression. The findings indicated that venlafaxine had a dose-dependent effect on 
supine diastolic blood pressure (Thase, 1998). Venalfaxine, therefore, may be avoided in 
depressed patients with hypertension. 
There are a few systemic reviews comparing the efficacy of duloxetine and SSRIs in the 
treatment of MDD. In a meta-analysis, duloxetine showed its comparable efficacy in the 
treatment of MDD patients as compared with SSRIs. However, its remission rates among 
patients with moderate to severe depression appears to be higher (Thase et al., 2007). 
Milnacipran is another SNRI effective for MDD. A meta-analysis of Puech et al. (1997) 
reviewed controlled trials comparing milnacipran with imipramine or SSRIs in MDD 
patients. The study findings showed that milnacipran was as effective as imipramine and 
might be superior to SSRIs. Milnacipran is as tolerable as SSIRS but more tolerable than 
TCAs in terms of general and cardiovascular side effects. Another meta-analysis of six 
studies including 1,082 outpatients with MDD compared the response rates between 
milnacipran and SSRIs (Papakostas & Fava 2007). The findings suggested that, for the 
treatment of MDD, milnacipran is as effective as SSRIs. 
From those reviews, SNRIs may be as effective as TCAs in the treatment of MDD. Their 
tolerability and safety are comparable to SSRIs. Venlafaxine and milnacipran may be 
superior to SSRIs in the treatment of MDD. However venlafaxine is associated with high 
blood pressure. 
3.1.1.4 Monoamine oxidase inhibitors  
Monoamine oxidase inhibitors (MAOIs) are a class of antidepressants. They appear 
particularly effective for atypical depression. There is a meta-analysis of eight studies 
comparing MAOIs with other antidepressants or placebo in the treatment of atypical 
depression. Most clinical trials were conducted on reversible MAOIs. The findings showed 
that MAOIs might be superior to TCA in the treating of MDD with atypical features (Henkel 
et al., 2006). 
Moclobemide, a reversible Inhibitor of MAO-A, have shown its efficacy in treating MDD in 
many trials. A meta-analysis, as compared with other antidepressants, moclobemide, 
imipramine, and clomipramine therapies may lead to a higher response rate in patients with 
depression (Angst et al., 1993). Another meta-analysis of 12 trials including 1,207 outpatients 
with MDD also showed that efficacy of moclobimide is comparable to that of SSRIs 
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(Papakostas & Fava, 2006). However SSRIs therapy might have greater rates of nausea, 
headaches, and treatment-emergent anxiety than that of moclobemide.  
From those reviews, MAOIs are effective for atypical depression. The evidences suggest that 
only moclobimide is as effective as TCAs and SSRIs for the treatment of MDD. 
3.1.1.5 Other antidepressants 
3.1.1.5.1 Escitalopram 
Escitalopram is effective in the treatment of MDD. A previous meta-analysis showed that, 
after six weeks of treatment, escitalopram was superior to placebo and comparable to TCAs. 
However escitalopram had fewer adverse events than those of TCAs (Bech & Cialdella, 
1992). A systemic review of four studies carried out in primary care settings also 
demonstrated that remission and response rates of escitalopram were superior to placebo 
and citalopram, but not venlafaxine-XR. However, its side effects are comparable with other 
antidepressants (Einarson, 2004). Another meta-analysis of ten clinical trials involving 2,687 
patients also supported the previous review results. The findings showed that escitalopram 
might be superior to SSRIs and comparable to venlafaxine in the treatment of patients with 
MDD (Kennedy et al., 2006).The results of a recently meta-analysis in eight-week treatment 
trials of MDD indicated that escitalopram (10-20 mg/day) is superior to and more tolerable 
than duloxetine (60 mg/day) (Lam et al., 2008). Another systemic review involving clinical 
trials of escitalopram versus SNRIs (two trials with duloxetine and two with venlafaxine 
extended release) in outpatients (18-85 years of age) with moderate-to-severe MDD 
summarized that, over the eight week treatment period,  escitalopram was as effective as but 
more tolerable than SNRIs (venlafaxine XR and duloxetine) (Kornstein et al., 2009). In addition, 
two meta-analyses showed that the efficacy and tolerability of escitalopram was superior to 
SSRIs and SNRIs (Kennedy et al., 2009; Lam et al., 2010). Escitalopram may also have a more 
rapid onset of action than other antidepressants (Kasper et al., 2006).The minimal effective 
dose for depression is 20 mg/day. However patients with severe or recurrent depression tend 
to respond to its higher dose (40 mg/day), and less severe depression may respond to its 
minimal effective dose (20 mg/day) (Montgomery et al., 1994). However, recent meta-analysis 
findings indicated that the effective doses of escitalopram may be lower than those in previous 
reviews. The recent review showed that the optimal dose of escitalopram in the treatment of 
moderate DSM-IV MDD is 10 mg/day, while the effective dose of escitalopram in patients 
with moderate to severe depression is 20 mg/day. 
According to several review findings, escitalopram is effective for MDD. Its efficacy may be 
greater than that of SSRIs. With a more tolerable profile, it appears to be superior TCAs and 
SNRIs. The dose range for moderate depression is 10-20 mg/day and for moderate to severe 
depression is 20-40 mg/day. 
3.1.1.5.2 Mirtazapine 
A number of systemic reviews have summarized the efficacy and safety of mirtazpine for 
MDD. A meta-analysis of four clinical studies comparing mirtazapine with amitriptyline 
and placebo suggested that mirtazapine was as effective as amitriptyline in the treatment of 
MDD. However, mirtazapine was better tolerated than amitriptyline with respect to adverse 
events, particularly anticholinergic and cardiac side effects (Stahl et al., 1997). Another meta-
analysis including 405 patients demonstrated that mirtazapine and amitriptyline were 
equally effective for severely depressed patients (Kasper et al., 1997). A systemic review of 
eight studies also showed that mirtazapine might be superior to placebo and comparable to 
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amitriptyline for patients with MDD predominant with anxiety/agitation or 
anxiety/somatisation symptoms (Fawcett & Barkin, 1998). In comparison to SSRIs, a 
systemic review of ten clinical trials including 1,904 outpatients with MDD showed that 
mirtazapine and SSRIs were equally effective, but mirtazapine had a preferable side effect 
profile (Papakostas, et al., 2008). In addition, a meta-analysis of 14 studies involving 1,108 
patients with MDD, mirtrazapine appears to have lesser sexual dysfunction than SSRIs 
(Chen et al., 2008). A meta-analysis of remission rates and time to remission of 15 six-week, 
clinical trials of mirtazapine and SSRIs showed a higher remission rates in mirtazapine-
treated patients after 1, 2, 3, 4 and 6 weeks of treatment. Mirtazapine may have a more rapid 
onset of action than SSRIs (Thase et al., 2010). 
With regard to those reviews, mirtazapine is as effective as amitriptyline and may be 
superior to SSRIs in the treatment of MDD. The side effect profile of mirtazapine appears to 
be different from those of amitriptyline and SSRIs. 
3.1.1.5.3 Bupropion 
Several systemic reviews supported the efficacy, safety and tolerability of bupropion. In a 
pooled study of clinical studies in MDD patients, at week 8 or end point, bupropion and 
SSRIs were equally effective and tolerable (Thase et al., 2005). In another meta-analysis of 
summarized that bupropion XL had a better sexual tolerability than that of escitalopram 
with similar antidepressant efficacy (Clayton et al., 2006). A systemic review of six clinical 
trials in MDD patients indicated that bupropion had a greater resolution of sleepiness and 
fatigue than SSRIs treatment (Papakostas et al., 2006). 
From those reviews, bupropion is an effective and tolerable antidepressant. Patients treated 
with bupropion appear to have less sexual dysfunction than those with SSRIs. It is also 
beneficial for sleepy and fatigue patients. 
3.1.1.5.4 Trazodone 
A meta-analysis summarized the efficacy, safety and tolerability of trazodone. Trazodone 
was compared with imipramine in six treatment studies of depression. The findings 
suggested that both active drugs were equally efficacious (Patten, 1992). A meta-analysis of 
nine studies including 988 patients showed that trazodone might be comparable to 
nefazodone and SSRIs (Papakostas & Fava, 2007). From two review, trazodone seems to be 
equi-effective and –tolerable as other antidepressants in the treatment of depression. 
3.1.1.5.5 Agomelatine  
Agomelatine, melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist, is 
indicated for the treatment of adult MDD. Most clinical trial results supported it efficacy in 
general depressed patients. A meta-analysis of three clinical studies also suggested that 25-
50 mg/day of agomelatine was also effective for severe depression. 
3.1.2 Cognitive-behavioural therapy 
CBT is effective for MDD. A meta-analysis of four short-term, randomized trials comparing 
antidepressants and CBT in severely depressed outpatients showed that CBT was as 
effective as antidepressants (DeRubeis et al., 1999). In comparison to psychodynamic 
psychotherapy, included studies with at least 13 therapy sessions and a at least 20 patients 
per group. The review findings suggested that short-term psychodynamic psychotherapy 
and CBT or behavioural therapy have similar remission or improvement judged by the 
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patients (Leichsenring, 2001). Another meta-analysis of Beltman (2010) including 29 studies 
found the effectiveness of CBT for the reduction of depressive symptoms in depressed 
patients with a diversity of somatic diseases. 
In addition, a meta-analysis comparing found that CBT, behavioral therapy, and 
psychodynamic therapy seem to be superior to pharmacological treatment  in elderly 
depressed patients. However, those nondrug and antidepressant therapies are comparable 
in treatment those depressed patients (Gerson et al., 1999). There is a systemic review of 57 
controlled trials to assess the effects of psychotherapy and other behavioral interventions in 
depressed older patients. About 19% of the participants discontinued their treatment, with 
the higher discontinuation rates in group therapies and in longer therapies. The reviews 
summarized that CBT and reminiscence seemed to be effective and acceptable for older 
patients with depression. Seven to twelve sessions appear to optimize effectiveness and 
minimize dropout rates (Pinquart et al., 2007). 
Several reviews have shown the efficacy of CBT in patients with depression. Its efficacy for 
the treatment of depression is comparable to that of antidepressants and other 
psychotherapy such as short-term psychodynamic psychotherapy. CBT may be beneficial or 
an alternative treatment for children, adolescents and elderly patients intolerable to 
antidepressants. 
Several reviews have shown that CBT is effective for depression in children and adolescents. 
A meta-analysis of six randomized trials compared the efficacy of CBT with inactive 
interventions in depressed patients aged between 8 and 19 years. Most included trials are 
based on relatively mild cases of depression and moderate quality. The review suggested 
that CBT may be beneficial for the treatment of depressive disorder with moderate severity 
in children and adolescents but not recommended for severe depression (Harrington et al., 
1998). Another meta-analysis also demonstrated that CBT appears to be effective for 
depressed adolescents (Lewinsohn & Clarke, 1999; Klein et al., 2007). Since there is a 
limitation for antidepressant use in children and adolescents, CBT may be an alternative and 
effective treatment of those patients with MDD. 
Although some clinical studies and reviews showed the efficacy of CBT in treating 
depressed patients, an overestimation of its efficacy from each study may not be overlooked. 
In a meta-analysis of Cuijpers et al. (2010) examined the effect sizes of 117 studies with 175 
comparisons between psychotherapy and control conditions demonstrated that the benefits 
of psychotherapy for adult depression appeared to be overestimated considerably due to 
publication bias. 
3.1.3 Cognitive-behavioural therapy combined with antidepressants 
Although antidepressant or CBT therapy alone shows its efficacy for MDD, significant 
proportion patients, particular those with severe or recurrent MDD, do not or partially 
respond to either monotherapy. Combined treatment is, therefore, a choice to raise the 
response and remission rates. Although many types of combined therapy for MDD are 
available, psychotherapy, particularly CBT, combined with antidepressants is effective and 
possibly less adverse effects than other combinations, e.g., combination of two 
antidepressants. The effectiveness of CBT combined with antidepressant is widely reported. 
A systemic review of 18 studies including 1,838 subjects receiving psychological treatment 
alone or combined treatment consisting of the same psychological treatment plus an 
antidepressant. The review showed that combined treatment is more effective than 
psychological treatment alone (Cuijpers et al., 2009). However the advantage of combination 
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appears to be less when an antidepressant is added to CBT (Cuijpers et al., 2009). The 
clinical study of Thompson et al. (2001) compared the efficacy of desipramine-alone, CBT-
alone and their combination for elderly outpatients with depression. The findings indicated 
that the combined therapy might be effective for severely depressed patients.  
The MDD patients who do not respond to an adequate dose and duration of antidepressant 
treatment are indicated for combined therapy. Many studies show that psychotherapy 
combined with antidepressants is effective for these patients. In the STAR*D study, the 
MDD patients who had received inadequate benefits from a initial antidepressant 
medication were assigned to treat with other strategies. The findings showed that CBT 
augmentation to citalopram is as effective as pharmacologic augmentation, although, the 
latter augmentation had more rapid remission than the CBT augmentation (Thase et al., 
2007). Regarding the evidence from other ethnic groups, an open study also demonstrated 
the adding CBT to fluoxetine in Thai patients with MDD who did not respond to four weeks 
treatment of fluoxetine has significantly more efficacy than previous fluoxetine treatment 
alone (Maneeton et al., 2010). 
4. Long-term treatment (continuation and maintenance phase) 
After the successful treatment of MDD in the acute phase, the discontinuation of 
antidepressant therapy usually leads to a relapse or recurrent. Long-term treatment is, 
therefore, desperately needed for most patients. The ultimate goal of treatment phase is to 
sustain the remission period and prevent a new episode of MDD. 
4.1 Antidepressants 
 Many reviews supported the antidepressant continuation for the prevention of early relapse 
for a period of 9-12 months after remission. Maintenance therapy of antidepressants is 
effective for preventing the recurrence of depressive episodes (Paykel, 2001). A systemic 
review of 31 studies including 4,410 participants demonstrated that antidepressant 
continuation treatment could reduce the relapse rate as comparison with placebo (41% for 
placebo vs. 18% for antidepressants) (Geddes, et al., 2003). Another meta-analysis of four 
comparative and 23 placebo-controlled trials reviewed the efficacy and effectiveness of 
second-generation antidepressants for preventing MDD relapse and recurrence during 
continuation and maintenance phases of treatment. Duloxetine and paroxetine, fluoxetine 
and sertraline, fluvoxamine and sertraline, and trazodone and venlafaxine were comparable 
for the relapse prevention of a depressive episode. A meta-analysis of those second-
generation antidepressants indicated the overall benefits of continuation- and maintenance-
phase treatment for patients with MDD (Hansen et al., 2008). In addition, a meta-analysis of 
30 studies involving 4,890 participants also summarized that antidepressants could reduce a 
relapse risk in the maintenance phase, regardless of clinical and pharmacologic factors. 
However, the larger number of depressive episodes may suggest a relative resistance 
against the prophylactic treatment from antidepressant (Kaymaz et al., 2008). 
A meta-analysis of Kok et al. (2011) reviewed eight studies of continuation and maintenance 
treatment in the elderly with 925 participating patients. The results showed that continuing 
treatment with antidepressants appeared to be efficacious as compared with placebo. The 
efficacy and tolerability during long-term treatment of both TCAs and SSRIs are 
comparable. 
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From those reviews, antidepressants appear to be effective in prevention relapse and 
recurrence of a depressive episode in MDD patients. However, the prophylactic effects of 
antidepressants in patients with many depressive episodes may not be as effective as those 
with a single episode. 
4.2 Cognitive behavioral therapy 
The review of Paykel (2001) showed that CBT appeared to be effective in preventing relapse 
from unipolar depression, particularly in patients with residual symptoms. A systemic review 
of 28 trials involving 1,880 adult patients suggested that acute treatment of CBT might be more 
effective than pharmacotherapy in reducing a relapse or recurrence of depressive episode. To 
compare with other active continuation treatments, continuation treatment with CBT in those 
responding to acute antidepressant therapy can reduce the relapse and recurrence at the end of 
continuation treatment and follow-up (Vittengl et al., 2007). 
Several evidences also show the advantage of long-term treatment with CBT for depression. 
The clinical study of Fava et al. (1996) determined whether CBT of residual symptoms of 
depression can prevent further relapses. Forty MDD patients with successfully 
antidepressant therapy were randomly assigned to either CBT or standard clinical 
management. Antidepressant medications in both groups were gradually tapered. The 
result showed that CBT was effective for the reduction of relapse in the depressed patients.  
As an intervention during the continuation and maintenance phase, CBT is beneficial for 
prevention of depressive episodes. 
4.3 Cognitive-behavioural therapy combined with antidepressants 
There is some evidence on the long-term benefits of psychotherapy combined with 
antidepressants. This combined therapy is particular effective in preventing a relapse of 
depressive episode. Although short-term antidepressant treatment is effective for MDD 
patients, some of them still behave and believe as if they depressed, and some still have low 
self-esteem or interpersonal difficulties. These residual symptoms, therefore, may be 
addressed with CBT. A 6-month, randomized controlled trial (RCT) compared the efficacy 
of continuation treatment with fluoxetine plus CBT or fluoxetine alone in 56 patients (ages 
11-18 years) with MDD who have responded to acute pharmacotherapy. The findings 
indicated that fluoxetine plus CBT might be able to reduce the risk of relapse as compared 
with fluoxetine alone (Kennard et al., 2008). In an open trial, 19 patients who failed to 
respond to at least two trials of antidepressants with adequate doses and durations were 
treated with CBT augmentation. The remaining 16 patients improved significantly, and 12 
patients were considered to be in remission (Fava et al., 1997).  
In contrast, there is a 6-month, continuation treatment study in patients with MDD who 
were remitted from an 8-week, open-label, fixed dose, acute treatment of fluoxetine. The 
study compared the continuation treatment of fluoxetine only and fluoxetine plus CBT. The 
findings showed no significant differences in the respects of relapse rates and 17 HAM-D 
scores (Petersen et al., 2004).  
5. Further research 
Several lines of evidence suggest that antidepressants, CBT and their combination are 
effective for the treatment and prevention of depressive episodes. Most studies involved the 
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treatment in acute phase and the rests were in the continuation and maintenance phases. 
Although several reviews and clinical studies in acute phase treatment of MDD have been 
done, most of them involve only either antidepressant or CBT monotherapy. In addition, 
only few clinical studies and systematic reviews of MDD treatments in continuation and 
maintenance phases, particularly the cognitive-behavioural therapy combined with 
antidepressants, have been carried out. Further RCTs and systemic reviews with well-
designed methodology, large sample sizes and consistent outcomes may be helpful in 
clarifying the benefits of this combination therapy in both acute and long-term treatments of 
MDD. 
6. Conclusion  
In the acute phase of MDD, combination of CBT and antidepressants appears to be more 
efficacious than antidepressant or CBT monotherapy, particularly in severely depressed 
patients. However this is a lack of evidence of this combination in depressed children and 
adolescents. 
For long-term treatment of MDD, antidepressant medications, CBT and its combination 
appear to be effective in preventing a depressive episode in both continuation and 
maintenance phase. Since there were only limited studies of this, we could not conclude that 
this combination is superior to antidepressant or CBT monotherapy in these phases. More 
well-designed studies are, therefore, necessary to determine the superiority of this 
combination over antidepressant and CBT monotherapy. 
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